EXHIBIT 10.1 AMENDED RESEARCH AND LICENCE AGREEMENT --------------------------------------Research and Licence Agreement • November 5th, 2003 • Tissera Inc • Telegraph & other message communications
RESEARCH AND LICENCE AGREEMENT Entered into on June 2, 2005 Between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly registered under the laws of Israel of P O Box 95, Rehovot 76100, Israel (hereinafter, “Yeda”) and BRAINSWAY, INC. a...Research and Licence Agreement • January 14th, 2019 • Brainsway Ltd. • Surgical & medical instruments & apparatus
ContractResearch and Licence Agreement • September 20th, 2007 • Protalix BioTherapeutics, Inc. • Biological products, (no disgnostic substances)
Portions of this exhibit have been omitted pursuant to a request for confidential treatment. The omitted portions, marked by [***], have been separately filed with the Securities and Exchange Commission.
Confidential material redacted and filed separately with the Commission. CONFIDENTIAL TREATMENT REQUESTED. Confidential portions of this document have been redacted and separately filed with the Commission. RESEARCH AND LICENCE AGREEMENT By and...Research and Licence Agreement • August 29th, 2005 • XTL Biopharmaceuticals LTD • Pharmaceutical preparations
WHEREAS in the course of research conducted at the Weizmann Institute of Science, Rehovot (hereinafter “the Institute”), ***** (hereinafter “*****”) has developed certain technology constituting the subject matter of the patent applications listed in the attachment hereto marked “A” and constituting an integral part hereof (hereinafter collectively “the Existing Applications” and “the Existing Technology”); and
AUTOGEN Pty Ltd and LIPHA S.A.Research and Licence Agreement • June 23rd, 2005 • Chemgenex Pharmaceuticals LTD • American depositary receipts
AUTOGEN Research Pty Ltd and LIPHA S.A.Research and Licence Agreement • June 23rd, 2005 • Chemgenex Pharmaceuticals LTD • American depositary receipts
THIRD AMENDMENT TO RESEARCH AND LICENCE AGREEMENTResearch and Licence Agreement • July 25th, 2018 • Cell Source, Inc. • Pharmaceutical preparations
WHEREAS Yeda and Cell Source are parties to a research and licence agreement dated October 3, 2011, as amended by a first amendment thereto dated April 8, 2014 and a second amendment dated November 28, 2016 ("the R&L Agreement”); and
RESEARCH AND LICENCE AGREEMENT between MICROMET AG and BIOVATION LIMITED August 14, 2001Research and Licence Agreement • March 16th, 2007 • Micromet, Inc. • Biological products, (no disgnostic substances) • England
BIOVATION LIMITED of Crombie Lodge, Aberdeen Science Park, Balgownie Drive, Aberdeen AB22 8GU, Scotland, UK (hereinafter “BIOVATION”).
RESEARCH AND LICENCE AGREEMENT Entered into on June 2, 2005 Between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly registered under the laws of Israel of P O Box 95, Rehovot 76100, Israel (hereinafter, “Yeda”) and BRAINSWAY, INC. a...Research and Licence Agreement • April 11th, 2011 • Brainsway Ltd. • Surgical & medical instruments & apparatus
WHEREAS: (A) the Company engages in the development and production of transcranial magnetic stimulation (“TMS”) apparatus and therapies for the treatment of depression, addictions and certain brain deficiencies and/or malfunctions; and (B) the Company is interested in the performance of research at the Weizmann Institute of Science (“the Institute”) under the supervision of Dr. Abraham Zangen (“the Scientist”) of the Department of Neurobiology in the field of depression, as specified in the research program attached hereto, marked Appendix A (“the Research Program” and “the Research”); and is willing, subject to and in accordance with the terms and conditions of this Agreement, to finance the performance of the Research in accordance with the budget attached hereto and marked Appendix B (“the Research Budget”); and
ContractResearch and Licence Agreement • March 30th, 2020 • Cell Source, Inc. • Pharmaceutical preparations
Certain information has been excluded from this exhibit because (i) it is not material and (ii) would be competitively harmful if publicly disclosed.
RESEARCH AND LICENCE AGREEMENTResearch and Licence Agreement • November 1st, 2019 • BiomX Inc. • Blank checks
WHEREAS: (A) in the course of research conducted at the Weizmann Institute of Science (“the Institute”), under the supervision of Dr. Eran Elinav of Department of Immunology and Professor Rotem Sorek of the Department of Molecular Genetics (“the Scientists”), the Scientists together with other scientists of the Institute (all of the aforementioned persons collectively “the Inventors”) created and/or generated the know-how and/or materials and other information described in Appendix A hereto, using the Institute’s state of the art preclinical germ-free mouse facility, anaerobic facility, robotic facility for high throughput phage discovery and sequencing facility (“the Existing Know-How”); and
SEVENTH AMENDMENT TO RESEARCH AND LICENCE AGREEMENT (this “Amendment”) Effective Date: November 15, 2020 by and between YEDA RESEARCH AND DEVELOPMENT COMPANY LIMITED a company duly registered under the laws of Israel of P O Box 95, Rehovot 76100,...Research and Licence Agreement • April 15th, 2021 • Cell Source, Inc. • Pharmaceutical preparations
WHEREAS Yeda and Cell Source are parties (the “Parties”) to a Research and Licence Agreement dated October 3, 2011, as amended by a First Amendment thereto dated April 8, 2014, a Second Amendment thereto dated November 28, 2016, a Third Amendment thereto dated March 29, 2018, a Fourth Amendment thereto dated March 30, 2018, a Fifth Amendment thereto dated June 30, 2019, and a Sixth Amendment dated December 31, 2019 (together, “the R&L Agreement”); and
FOURTH AMENDMENT TO RESEARCH AND LICENCE AGREEMENT (this “Amendment”)Research and Licence Agreement • July 25th, 2018 • Cell Source, Inc. • Pharmaceutical preparations
WHEREAS Yeda and Cell Source are parties (the “Parties”) to a research and licence agreement dated October 3, 2011, as amended by a first amendment thereto dated April 8, 2014 a second amendment thereto dated November 28, 2016, and a third amendment dated March 29, 2018 (together, "the R&L Agreement”); and
SECOND AMENDMENT TO RESEARCH AND LICENCE AGREEMENT (this “Amendment”)Research and Licence Agreement • July 25th, 2018 • Cell Source, Inc. • Pharmaceutical preparations
WHEREAS Yeda and Cell Source are parties to a research and licence agreement dated October 3rd, 2011, as amended by a first amendment thereto dated April 8, 2014 (together, "the R&L Agreement”); and
